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ABSTRACT
We report the evaluation of 20-, 18-, 16- and 14-
mer phosphorothioate (PS)-modified tricycloDNA
(tcDNA) gapmer antisense oligonucleotides (ASOs)
in Tm, cell culture and animal experiments and
compare them to their gap-matched 20-mer 20-O-
methoxyethyl (MOE) and 14-mer 20,40-constrained
ethyl (cEt) counterparts. The sequence-matched
20-mer tcDNA and MOE ASOs showed similar Tm
and activity in cell culture under free-uptake and
cationic lipid-mediated transfection conditions,
while the 18-, 16- and 14-mer tcDNA ASOs were
moderate to significantly less active. These obser-
vations were recapitulated in the animal experi-
ments where the 20-mer tcDNA ASO formulated in
saline showed excellent activity (ED50 3.9mg/kg) for
reducing SR-B1 mRNA in liver. The tcDNA 20-mer
ASO also showed better activity than the MOE
20-mer in several extra-hepatic tissues such as
kidney, heart, diaphragm, lung, fat, gastrocnemius
and quadriceps. Interestingly, the 14-mer cEt ASO
showed the best activity in the animal experiments
despite significantly lower Tm and 5-fold reduced
activity in cell culture relative to the 20-mer tcDNA
and MOE-modified ASOs. Our experiments establish
tcDNA as a useful modification for antisense thera-
peutics and highlight the role of chemical modifica-
tions in influencing ASO pharmacology and
pharmacokinetic properties in animals.
INTRODUCTION
Over the recent years, chemically modiﬁed oligonucleo-
tides have been extensively investigated as potential
drugs (1). Currently, more than 30 candidates are
in clinical trials targeting a large variety of diseases
including cancer, metabolic diseases and genetic disorders.
Mipomersen, a second generation antisense oligonucleo-
tide that targets apolipoprotein B, has shown impressive
reductions in serum apolipoprotein B, LDL-cholesterol
and other atherogenic lipids in multiple phase III clinical
trials (2). The general mode of action of antisense oligo-
nucleotides is based on speciﬁc Watson–Crick recognition
of target RNAs, which results in modulation of the
function of the target RNA. In the original antisense
approach, a single-stranded oligonucleotide targets a
mRNA and suppresses its translation either via a steric
block or by RNase H-mediated RNA degradation.
Variations of steric block inhibitors include oligonucleo-
tides that interfere with splicing of a pre-mRNA, leading
to selective exon inclusion or exclusion, or alternative
splicing. In addition, oligonucleotide-dependent degrad-
ation of target RNA can be induced by small double-
stranded interfering RNAs (siRNAs) which guide an
mRNA of interest into the RNA-induced silencing
complex (RISC) where it is cleaved (3). Yet, another
approach is based on targeting micro-RNAs (miRNAs)
that are genetically encoded and function as natural
regulators of translation, by single-stranded antisense
oligonucleotides (4–6).
The speciﬁc chemical features of single-stranded anti-
sense oligonucleotides fundamentally determine their
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biological function (7). The most important factors are
afﬁnity for target RNA, biostability against nuclease deg-
radation and bioavailabilty in animals. First generation
classical antisense oligodeoxyribonucleotide phosphoro-
thioates (PS 1, Figure 1) elicit RNaseH activity and
show increased biostability, however, their afﬁnity to com-
plementary RNA is moderate. On the other hand, high-
afﬁnity RNA binders such as 20-modiﬁed RNA (8),
20,40-bridged nucleic acids (BNA, also known as locked
nucleic acid or LNA) (9), hexitol nucleic acids (HNA)
(10) or tricyclo-DNA (tcDNA) (11) do not elicit
RNaseH activity when used as mixmers. To circumvent
this drawback, oligonucleotide gapmers have been
introduced that show a window of natural nucleotides in
the center of the sequence ﬂanked by chemically modiﬁed
wings on either side (12). Such chimeric oligonucleotides
combine the features of high-RNA afﬁnity and
biostability while maintaining the ability to degrade the
targeted mRNA via an RNaseH mechanism.
As part of a comprehensive program aimed at eluci-
dating the structure–activity relationships (SAR) of chem-
ically modiﬁed ASOs in animals, we have recently
reported the evaluation of RNase H active gapmer
ASOs containing 20,40-bridged nucleic acids and hexitol
analogs (13–17). tcDNA represents another oligonucleo-
tide scaffold that exhibits favorable physico-chemical
properties, such as improved target RNA afﬁnity and
nuclease stability, for the antisense approach (18,19).
Yet, gapmer ASOs containing PS-modiﬁed tcDNA have
not been evaluated in cellular or in animal experiments. In
this light, we present here a comprehensive analysis of the
biophysical, pharmacological and tissue distribution
properties of 14- to 20-mer phosphorothioate tcDNA
gapmer ASOs and compare them to sequence matched
MOE and 20,40-constrained ethyl BNA (cEt) control
ASOs. We show that tcDNA-modiﬁed ASOs formulated
in saline show potent and robust antisense effects in
hepatic as well as extra-hepatic tissues without producing
toxicity and highlight the role of chemical modiﬁcations in
inﬂuencing ASO pharmacology and pharmacokinetic
properties in animals.
MATERIALS AND METHODS
Oligonucleotide synthesis and puriﬁcation
The syntheses of the tc-DNA gapmer oligonucleotides were
performed on a 10.0mmol scale on a Gene Assembler Plus
DNA synthesizer (Pharmacia/GE healthcare) using
standard phosphoramidite chemistry. Tc-nucleoside-
modiﬁed long chain alkylamino CPG (Link Technologies)
was used as solid support. Tc-phosphoramidites [0.15M in
CH3CN for T, C and G and dichloroethane (DCE) for A]
were coupled with 5-(ethylthio)-1H-tetrazole (ETT, 0.25M
in CH3CN) as activator with a coupling time of 12min.
Sulfurization was carried out using phenylacetyl disulﬁde
(PADS, 0.2M solution in dry pyridine/CH3CN 1:1, v/v)
for 3.5min. After synthesis was completed, the support-
bound oligonucleotides were treated with a solution of
Et3N/CH3CN (1:1, v/v) for 2 h and then deprotected and
detached from solid support with 33% aqueous NH3 for
16h at 55C. The crude material was puriﬁed by
ion-exchange HPLC (Source 30Q, GE Healthcare) with
linear gradients (0–50%) of buffer B (0.1M NH4OAc,
H2O:CH3CN 7:3, pH 8.0, 1.5M NaBr) in buffer A (0.1M
NH4OAc, H2O:CH3CN 7:3 pH 8.0) as eluent. Oligonucleo-
tides were desalted over HiPrepTM 26/10 columns
(GE Healthcare) and lyophilized. Sequences and analytical
data are summarized in Supplementary Table S1. ASOs A5
and A6 were synthesized according to procedures described
previously (16,20).
Cells and reagents
MHT cells (21) were cultured in DMEM supplemented
with 10% fetal calf serum, streptomycin (0.1 mg/ml) and
penicillin (100U/ml). ASO transfection was performed
using Opti-MEM containing 5 mg/ml Lipofectamine 2000
at the indicated amount of ASO for 4 h at 37C, as
described previously (22,23).
Taqman RT–PCR
Total mRNA was isolated using a QIAGEN RNAeasy kit
(QIAGEN, Valencia, CA, USA). Reduction of target
mRNA expression was determined by real time RT–
PCR (1) using StepOne RT–PCR machines (Applied
Biosystems). The sequences used in the RT–PCR
reaction are 50-TGACAACGACACCGTGTCCT-30 for
the forward primer, 50-ATGCGACTTGTCAGGCTG
G-30 for the reverse primer and 50-CGTGGAGAACCG
CAGCCTCCATT-30 for the probe. The expression data
were normalized to ribogreen (Invitrogen). Data are mean
values± standard deviations of three replicates. IC50
values were calculated using GraphPad Prism 4 software.
Protocols for animal experiments
The Institutional Animal Care and Use committee
(IACUC) approved all procedures. Male Balb/c mice
were housed 4/cage on a 12:12-h light/dark cycle. For
the ﬁrst study, tcDNA, MOE, and cEt ASO solutions
were prepared in PBS and injected subcutaneously (s.c)
twice a week at a concentration of 25, 5, 1 or 0.5mg/kg
for 3 weeks. For the follow-up study, mice were injected
s.c at 25mg/kg twice a week for 3 weeks. Mice were
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Figure 1. Structures of oligonucleotide modiﬁcation evaluated in this
study.
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sacriﬁced 48 h after the last dose. Blood samples were col-
lected by cardiac puncture and plasma chemistries
(alanine amino transferase, aspartate amino transferase,
bloood urea nitrogen, total bilirubin, cholesterol and tri-
glycerides) values were measured on the Olympus AU400
Clinical Analyzer (Beckman Coulter, CA, USA).
RNA analysis for animal experiments
Liver, kidney, diaphragm, lung, white adipose, heart,
quadriceps and gastrocnemius muscle were dissected,
weighed and immediately homogenized in 2ml of
PureLink RNA lysis buffer (Life Technologies, CA,
USA). Total RNA was isolated using the Purlink RNA
Mini Kit (Life Technologies). Reduction of target mRNA
expression was determined by real time RT–PCR using
7700 RT–PCR sequence detector (Applied Biosystems).
Data are mean values± standard deviations of three rep-
licates. The sequences used in the RT-PCR reaction are
50-TGACAACGACACCGTGTCCT-30 for the forward
primer, 50-ATGCGACTTGTCAGGCTGG-30 for the
reverse primer and 50-CGTGGAGAACCGCAGCCTCC
ATT-30 for the probe. RNA transcripts were normalized
to total RNA levels using RiboGreen, RNA Quan-
titation Reagent (Molecular Probes). RiboGreen is an
ultrasensitive ﬂourescent nucleic acid stain which when
bound to RNA has a maximum excitation/emission at
500 nm/525 nm. ED50 values were calculated using
GraphPad Prism 4 software.
RESULTS
Oligonucleotide design considerations
The prototypical design of a second generation anti-
sense oligonucleotide employs a 8–14 base PS-modiﬁed
deoxynucleotide ‘gap’ ﬂanked on either end with 2–5
MOE nucleotides (MOE gapmer) (24–26). Typically,
each MOE nucleotide confers+1–2C/mod. towards the
overall duplex thermal stability depending on the position
and sequence context of the incorporation. The PS
backbone promotes binding to plasma proteins thereby
reducing renal excretion of the oligonucleotide (27). This
allows the ASO to distribute to peripheral tissues such that
one observes reproducible and robust antisense effects in
animal models especially when targeting genes expressed
in the liver. More recently, we and others have shown that
replacing MOE with high-afﬁnity BNA nucleotides in the
‘wings’ of second generation ASOs allows for the use of
oligonucleotides as short as 12- to 14-mer in length
(13,28). In these designs, the BNA nucleotide contributes
+3–4C/mod. towards duplex thermal stability. However,
the reduced PS content of the shorter ASOs designs results
in reduced exposure to peripheral tissues. Despite
this, somewhat counterintuitively, these ASOs exhibit
improved activity in animal experiments although anti-
sense effects towards gene targets expressed in tissues
other than liver have not been well-characterized to
date. In comparison to BNA, tcDNA exhibits intermedi-
ate improvement (Tm+2–4
C/mod.) in duplex thermal
stability as measured by incorporation in the interior of a
phosphodiester deoxyribo-oligonucleotide (29). However,
RNase H-active gapmer ASOs are typically uniformly PS
modiﬁed and position the modiﬁed nucleotides in the
wings where the effects of tcDNA on duplex thermal sta-
bility have not been well-characterized. Given this back-
ground, it was difﬁcult to ascertain a priori what ASO
length and tcDNA content would be optimal. As a
result, we prepared the gap-matched 20-, 18-, 16- and
14-mer tcDNA (ASOs A1–A4, Table 1) versions of a pre-
viously identiﬁed potent 5-10-5 MOE gapmer (A5) target-
ing scavenger receptor B1 (SR-B1), a ubiquitously
expressed gene whose physiological role is related to chol-
esterol uptake into tissues (30). The SR-B1 receptor has
also been implicated as an entry point for viruses such as
HCV (31) and other pathogens (32) and its down-
regulation could provide a therapeutic beneﬁt by prevent-
ing entry of infectious pathogens into host cells.
In addition to the 5-10-5 MOE control, we also evaluated
a gap-matched 2-10-2 14-mer cEt ASO A6 as an add-
itional control for the comparative study.
Table 1. Sequence, design features, Tm, activity for reducing SR-B1 mRNA in MHT cells and in mouse liver for tcDNA, MOE and
cEt-modiﬁed PS gapmer ASOs
ASO Sequence (50to 30)a Mod. Length Design Tm (C)b IC50 (nM)
c IC50 (nM)
d ED50
(mg/kg)e
A1 p-GCTTCAGTCATGACTTCCTT tcDNA 20-mer 5-10-5 71.2 0.57 54.5 3.9
A2 p-CTTCAGTCATGACTTCCT tcDNA 18-mer 4-10-4 63.9 0.73 238.0 4.5
A3 p-TTCAGTCATGACTTCC tcDNA 16-mer 3-10-3 58.2 5.34 407.7 7.1
A4 p-TCAGTCATGACTTC tcDNA 14-mer 2-10-2 49.7 11.58 >1000 16.4
A5 GmCTTmCAGTmCATGAmCTTmCmCTT MOE 20-mer 5-10-5 69.7 0.63 45.0 3.5f
A6 TmCAGTmCATGAmCTTmC S-cEt 14-mer 2-10-2 59.0 2.48 138.5 <1.0g
aBold and underlined alphabet indicates modiﬁed nucleotides.
bTm values were measured in 10mM sodium phosphate buffer (pH 7.2) containing 100mM NaCl and 0.1mM EDTA, Sequence of RNA complement
50-r(UUGAAAGGAAGTCATGACTGAAGC)-30; all internucleosidic linkages in ASOs A1–A6 are phosphorothioate except the 50-terminal phos-
phate in ASOs A1–A4.
cIC50 values for reducing SR-B1 mRNA in MHT cells after transfection of ASO with lipofectamine.
dIC50 values for reducing SR-B1 mRNA in MHT cells under free-uptake conditions.
eED50 values for reducing SR-B1 mRNA in mouse liver.
fED50 values obtained from a different experiment.
gEstimated ED50 based on reduction of SR-B1 mRNA (54±6.6% at 1mg/kg dose) observed in this study. See Supplementary Figures S1, S2, S4
and S5 for dose–response curves.
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Duplex thermal stability measurements of modiﬁed
ASOs with RNA
We ﬁrst evaluated all the ASOs in thermal stability experi-
ments using a 24-mer RNA complement (Table 1). We
chose the longer complement since the biological target
for these ASOs, i.e. the mRNA, is not length matched to
the ASOs (33). As would be expected, increasing the
length and tcDNA content in the modiﬁed ASOs led to
increases in duplex thermal stability. However, somewhat
surprisingly, the increase in afﬁnity was highly dependent
on the context of the incorporation. For example, the
14-mer 2-10-2 tcDNA ASO A4 showed a Tm of 49.7
C,
but the Tm of the 16-mer 3-10-3 ASO A3 was 58.2
C,
corresponding to a Tm of +4
C for each of the added
nucleotide. For the 18-mer 4-10-4 (Tm 63.9
C) and the
20-mer 5-10-5 (Tm 71.2
C) tcDNA ASOs A2 and A1,
respectively, each tcDNA nucleotide contributed roughly
+2.5C and+3.5C, respectively, towards the increase in
overall duplex thermal stability. In comparison, the Tm of
the 5-10-5 MOE and the 2-10-2 cEt ASOs A5 and A6 were
69.7 and 59.0C, respectively. It should be noted that
ASOs A5 and A6 were synthesized using 5-Me groups
(Tm+0.5
C/mod.) (34) on the cytosine nucleobases in
the gap and in the wings (6 for MOE ASO A5 and 4 for
cEt ASO A6) while the tcDNA ASOs were not. Thus, it is
anticipated that, if needed, the RNA afﬁnity of the tcDNA
ASOs can be further increased by introducing 5-Me
groups on the cytosine nucleobases.
Cell culture evaluation of ASOs A1–A6
We next evaluated all the ASOs in MHT cells under
free-uptake conditions and with cationic lipid transfection
to deliver the oligonucleotides (21). Using cationic lipid
transfection, all the tcDNA ASOs showed activity in cell
culture consistent with their duplex thermostability meas-
urements (Table 1 and Supplementary Figure S1). The
20-mer tcDNA ASO A1 had the highest Tm and showed
the best activity in cell culture (IC50=0.57 nM), followed
by the 18-mer ASO A2 (IC50=0.73 nM), 16-mer
ASO A3 (IC50=5.34 nM) and the 14-mer ASO A4
(IC50=11.6 nM). Also consistent with the Tm data, the
5-10-5 MOE ASO A5 (IC50=0.63 nM) showed activity
comparable to 20-mer tcDNA ASO A1. The 14-mer
cEt ASO A6 showed 5-fold reduced activity
(IC50=2.48 nM) relative to the 20-mer tcDNA or MOE
ASO A1 and A5, respectively. However, the activity of
ASO A6 was 2-fold better than that of the 16-mer
tcDNA ASO A3 even though both the ASOs had almost
identical Tm.
In the absence of the cationic lipid transfection, all the
ASOs showed almost 100-fold reduction in activity but the
overall potency trends were similar to those observed in
the transfection assay (Table 1 and Supplementary Figure
S2). In the tcDNA series, the 20-mer ASO A1 showed
the best activity (IC50=55 nM) followed by A2
(IC50=238 nM) and A3 (IC50=408 nM), while A4
showed very poor activity (IC50> 10 000 nM). As before,
the MOE 20-mer ASO A5 (IC50=45 nM) showed activity
comparable to ASO A1 while the 14-mer cEt ASO A6
(IC50=139 nM) was 3-fold less active. Once again,
ASO A6 showed 3-fold better activity as compared to
the 16-mer ASO A3 despite similar overall Tm.
We also measured oligonucleotide copy numbers in
each cell to ascertain if ASOs with different lengths and
chemical modiﬁcations in the ﬂanks were taken up differ-
entially into MHT cells under free-uptake conditions
(Supplementary Figure S3). Somewhat surprisingly, we
found that all the tcDNA ASOs showed very similar
uptake into MHT cells irrespective of oligonucleotide
length. Thus, it appears that introducing more than four
tcDNA monomers into an ASO does not increase cellular
uptake or accumulation, but the increased tcDNA content
is required to boost RNA afﬁnity to produce an antisense
effect. In contrast to the tcDNA ASOs, the MOE and cEt
ASOs A5 and A6, respectively, showed almost 2-fold
lower ASO copy numbers/cell. Thus, the improved
activity of the cEt ASO A6 relative to the tcDNA
14-mer, 16-mer or the 18-mer ASOs cannot be explained
by increased uptake of this ASO into MHT cells under
free-uptake conditions.
Evaluation of ASOs A1–A6 in animal experiments
We next evaluated the ASOs A1–A6 in animal experi-
ments. Mice (n=4/group) were injected sub-cutaneously
(s.c.) with 0.5, 1.0, 5.0 and 25.0mg/kg of tcDNA ASOs,
5 and 25mg/kg of MOE ASO A5 and 1 and 25mg/kg of
cEt ASO A6 formulated in saline twice a week for 3 weeks
(Figure 2). While the MOE and cEt ASOs A5 and A6 were
only evaluated at two doses in this study, ASO A5 was
previously evaluated in a separate dose-reponse experi-
ment where it showed good potency (ED50=3.5mg/kg;
Supplementary Figure S4). While a complete dose–
response for the cEt ASO A6 is not available, the ED50
can be estimated (ED50< 1mg/kg) based on the reduction
of SR-B1 mRNA (54±6.6% at the 1mg/kg dose)
observed in this study (Table 1). The animals were
sacriﬁced 48 h after the last ASO dose and the SRB1
mRNA in liver was measured by quantitative RT–PCR
and normalized to the saline treated group (Figure 2A and
Supplementary Figure S5). In addition, we also recorded
other parameters, such as plasma transaminases and
organ weights, as gross indicators of ASO tolerability.
As seen in the cell culture experiments, the tcDNA
ASOs showed dose-dependent reductions of the SR-B1
mRNA in liver with the 20-mer A1 exhibiting the best
potency (ED50=3.9mg/kg) followed by the 18-mer A2
(ED50=4.5mg/kg), 16-mer A3 (ED50=7.1mg/kg) and
14-mer A4 (ED50=16.4mg/kg). Thus, in the tcDNA
length series, the animal experiments recapitulated the
potency trend observed in the free-uptake cell culture
study even though the magnitude of the potency difference
was not similar.
To see if the activity seen in liver could be extended to
other tissues, we also measured the down-regulation of
SR-B1 mRNA in quadriceps and heart muscle
(Figure 2B and C). Once again, we observed dose-
dependent reductions in SR-B1 mRNA in both heart
and quadriceps although the potency relative to liver
was reduced for all the ASOs tested. The down-regulation
of SR-B1 gene expression results in an increase in the
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plasma cholesterol levels of the treated mice. The
high-dose ASO-treated group showed between 3- and
5-fold increases in plasma cholesterol levels (Figure 2G)
relative to saline which were consistent with the expected
phamacological response for reducing SR-B1 gene expres-
sion. In contrast, there were no noticiable effects on the
levels of plasma triglycerides (Figure 2H) indicating that
the increase in plasma cholesterol levels were indeed
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Figure 2. Reduction of SR-B1 mRNA and tolerability proﬁle after treatment with ASOs A1–A6. Mice (BalbC, n=4/group) were dosed s.c. with 0.5,
1.0, 5.0 and 25.0mg/kg of ASOs A1–A4, 5.0 and 25.0mg/kg of ASO A5 and 1.0 and 25.0mg/kg of ASO A6, twice a week for 3 weeks and animals
were sacriﬁced 48 h after last dose. Organs were harvested and SR-B1 mRNA was quantiﬁed by qRT–PCR and normalized to the saline-treated
group. The 0.5mg/kg dose group for ASO A4 was not counted in the ﬁnal analysis due to a dosing error. SR-B1 mRNA reduction in (A) liver
(B) quadriceps and (C) heart. Plasma levels post sacriﬁce for (D) ALT. Organ weights for (E) liver (F) spleen. Plasma levels post-sacriﬁce for
(G) cholesterol and (H) triglycerides. Error bars indicate ±standard deviation.
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related to SR-B1 down-regulation. In general, all the
ASOs were well-tolerated with no elevations in transamin-
ase levels (ALT) and liver weights (Figure 2D and E).
Slight elevations in spleen weights were observed for the
high-dose group ASO A1-treated mice although these
could be, in part, related to the pharmacological effects
of the ASO or to the lack of 5-Me groups on the cytosine
nucleobases in the tcDNA-modiﬁed ASOs (Figure 2F).
5-Me groups on the deoxycytidine nucleobase are known
to mitigate the immune stimulation properties of CpG
oligonucleotides (35).
To ascertain if tcDNA 14-mers were generally less
active as compared to 14-mer ASOs with other higher
afﬁnity modiﬁcations in the wings, we evaluated a
14-mer tcDNA ASO A7 targeting mouse phosphatase
and tensin homologue (PTEN) and compared it to a
14-mer LNA benchmark ASO A8 (Supplementary
Figure S6). This sequence has been used extensively by
us to proﬁle the antisense properties of ASOs modiﬁed
with various BNA and HNA analogs (13–17). We found
that the tc-DNA 14-mer showed lower Tm and reduced
activity in cell culture and in the animal experiment as
compared to the LNA benchmark ASO. However,
unlike the LNA ASO A8, the tcDNA ASO did not show
elevations in ALT levels for the high-dose group-treated
animals.
We also quantiﬁed the level of ASOs A1–A6 in liver
tissue (Supplementary Figure S7). Consistent with
previous studies of PS-modiﬁed gapmer ASOs, drug accu-
mulation in liver was dependent on dose and the overall
PS content of the ASO. Thus, both the 20-mer ASOs A1
and A5 showed very similar levels of accumulation at the
25 and 5mg/kg dose. However, the effect of wing chem-
istry on tissue accumulation was more evident for the
shorter tcDNA ASOs which showed higher drug levels
in liver tissue. For example, the16-mer and 18-mer
tcDNA ASOs A2 and A3 showed similar liver accumula-
tion as the 20-mer ASOs A1 and A6 but the 14-mer
tcDNA ASO A4 showed almost 3-fold higher accumula-
tion in liver tissue as compared to the 14-mer cEt ASO A6.
It is possible that the more hydrophobic nature of the
tcDNA monomers enhances binding to plasma proteins
but this effect is most prominent for shorter ASOs as
compared to the longer designs where increased PS
content dominates ASO distribution.
To further understand ASO distribution between differ-
ent cell types in the liver and kidney, we stained tissue
sections from mice treated with the 20-mer tcDNA and
MOE ASOs A1 and A5, respectively, and 14-mer cEt ASO
A6 using a rabbit polyclonal antibody raised against the
MOE ASO A5 (Supplementary Figure S8). We found no
qualitative changes in ASO distribution between the dif-
ferent cell types in the liver but darker staining for oligo-
nucleotide was observed in the non-parenchymal cells of
the liver for all the ASOs evaluated. However, the differ-
ential recognition of the antibody for ASOs A1, A5 and
A6 does not allow for any quantitative estimation of
changes in sub-organ distribution to be made at this point.
To conﬁrm the observations from the ﬁrst study and to
examine the effect of the ASO treatment on SR-B1
mRNA down-regulation in tissues other than liver, heart
and quadriceps, we carried out a follow-up study
(Figure 3). Mice (n=4/group) were injected s.c. with
ASOs A1–A6 formulated in saline at 25mg/kg twice a
week for 3 weeks. Animals were sacriﬁed 48 h after the
last ASO dose and down-regulation of SR-B1 mRNA in
liver, kidney, diaphragm, lung, fat, heart, quadriceps and
gastrocnemius was measured by quatitative RT-PCR and
the results were normalized to saline-treated animals
(Figure 3A). As seen in the previous study, we observed
>95% down-regulation of the SR-B1 mRNA for all the
ASO-treated groups in liver tissue. In kidney, ASOs
A1–A3 and A6 showed similar activity for reducing
SR-B1 mRNA while A4 and A5 were less active.
A similar trend was observed in lung tissue while in the
diaphragm all but ASO A4 showed similar activity. In fat,
heart, quadriceps and gastrocnemius, the tcDNA ASOs
A1–A4 showed activity directly propotional to ASO
length. The 14-mer cEt ASO A6 showed activity compar-
able to the 20-mer tcDNA A1 in all the tissues evaluated.
Once again, all the ASOs were well-tolerated with no
elevations in plasma ALT (Figure 3B) or organ weights
(Figure 3C–E).
DISCUSSION
Our evaluation of tcDNA gapmer ASOs presents
several interesting observations. When combined with
the phosphorothioate backbone modiﬁcation, tcDNA
gapmer ASOs show similar to slightly improved
duplex thermal stability relative to length-matched MOE
gapmer ASO but reduced thermostability relative to
length-matched cEt or LNA gapmer ASOs. This observa-
tion is generally in line with the duplex stabilizing
properties reported for these modiﬁcations in oligonucleo-
tide sequences used for biophysical studies. In cell culture,
tcDNA ASOs showed activity which was consistent with
their duplex thermostability measurements under transfec-
tion and free-uptake conditions. For example, the 20-mer
tcDNA and MOE ASOs A1 and A5, respectively, showed
the highest Tm and best activity for reducing SR-B1
mRNA in cell culture followed by the 18-mer A2,
16-mer A3 and 14-mer A4 tcDNA ASOs. In general, the
Tm and cell culture observations were recapitulated in the
animal experiments where the 20-mer tcDNA and MOE
ASOs A1 and A5, respectively, exhibited better activity
relative to the 18-mer, 16-mer and 14-mer tcDNA ASOs
A2, A3 and A4. However, somewhat surprisingly, the
shorter 14-mer cEt ASO A6 showed the best overall
activity in the animal experiments despite lower Tm and
5-fold reduced potency relative to the 20-mer tcDNA
and MOE ASOs A1 and A5, respectively, in cell culture.
The 14-mer cEt ASO A6 also showed 3-fold improved
activity in cell culture as compared to 16-mer tcDNA ASO
A3 even though both ASOs had identical RNA-binding
afﬁnity. Moreover, improved activity in animal experi-
ments was observed despite reduced overall liver accumu-
lation for the 14-mer cEt ASO A6. ASOs, unlike small
molecules drugs, cannot distribute to all the different
cellular compartments by passive diffusion. ASOs are
known to enter cells via multiple pathways some of
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which are productive and lead to sequence speciﬁc gene
down-regulation of the targeted mRNA in the nucleus
(21,36). In contrast, non-productive pathways lead to
ASO accumulation into endosomal and lysosomal com-
partment where they are most likely metabolized by
nuclease-mediated digestion and excreted. It is also
known that phosphorothioate-modiﬁed single-stranded
ASOs interact with several proteins within the cell some
of which might be responsible for differential trafﬁcking of
the ASO to different sub-cellular compartments leading to
different pharmacological and toxicological properties
(21,36). It is possible that ASO length and chemical modi-
ﬁcation can have a differential impact on these inter-
actions resulting in the observed effects. Another
interesting result from this study was the robust antisense
activity seen in multiple tissues with several of the ASOs
evaluated. Perhaps, more importantly, these effects were
observed in the absence of elevated plasma transaminases
indicating that it is possible to achieve robust antisense
effects in tissues other than liver without producing
hepatoxicity. Thus, our data show that phosphoro-
thioate-modiﬁed gapmer ASOs can down-regulate gene
Figure 3. Reduction of SR-B1 mRNA and tolerability proﬁle after treatment with ASOs A1–A6. Mice (BalbC, n=4/group) were dosed s.c. with
25.0mg/kg of ASOs A1–A6, twice a week for 3 weeks and animals were sacriﬁced 48 h after last dose. Organs were harvested and SR-B1 mRNA in
was quantiﬁed by qRT–PCR and normalized to the saline-treated group. SR-B1 mRNA reduction in (A) liver, kidney, diaphragm, lung, fat, heart,
quadriceps and gastrocnemius. Plasma levels post-sacriﬁce for (B) ALT. Organ weights for (C) liver, (D) kidney and (E) spleen. Error bars indi-
cate± standard deviation.
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expression in a therapeutically relevant manner in hepatic
and extra-hepatic tissues and this can be further
modulated by ASO length and wing chemistry.
CONCLUSIONS
In conclusion, we show for the ﬁrst time that tcDNA
phosphorothioate-modiﬁed gapmer ASOs show robust
antisense effects for reducing gene expression in multiple
tissues without producing hepatotoxicity. With the excep-
tion of the cEt ASO A6, all ASOs evaluated showed
activity consistent with their Tm and cell culture proﬁle.
The origins of the improved potency despite lower Tm, cell
culture activity and reduced tissue exposure observed with
the cEt ASO A6 in liver are not properly understood as of
yet. However, they are likely related to differential
sub-cellular ASO distribution which is in turn inﬂuenced
by ASO length and speciﬁc structural features of the
modiﬁed nucleotides in the ﬂanks of the ASO. Our data
provides an impetus to further explore phosphorothioate-
modiﬁed tcDNA and related modiﬁcations for therapeutic
antisense applications using the RNase H and other
antisense mechanisms.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online:
Supplementary Table 1 and Supplementary Figures 1–8.
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